LAVA Therapeutics N.V. (LVTX)

NL — Healthcare Sector
Peers: ANEB  PMVP  MIRO  ZIVO  BNOX  EWTX  IKNA  DSGN  XLO  ELYM  AVTE  ADAG  ACRV  RZLT  ANTX  GBIO  KRON  ERAS  CCCC  NLTX  TIL  ACHL  NXTC  ASMB 

Automate Your Wheel Strategy on LVTX

With Tiblio's Option Bot, you can configure your own wheel strategy including LVTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LVTX
  • Rev/Share 0.1856
  • Book/Share 0.9588
  • PB 1.3455
  • Debt/Equity 0.0121
  • CurrentRatio 6.7316
  • ROIC -0.4596

 

  • MktCap 33933837.0
  • FreeCF/Share -0.6105
  • PFCF -2.067
  • PE -1.2372
  • Debt/Assets 0.0044
  • DivYield 0
  • ROE -0.8668

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade LVTX Leerink Partners Outperform Market Perform $11 $2 Dec. 12, 2024
Downgrade LVTX JMP Securities Mkt Outperform Market Perform -- -- Dec. 11, 2024

News

About LAVA Therapeutics N.V. (LVTX)

  • IPO Date 2021-03-26
  • Website https://www.lavatherapeutics.com
  • Industry Biotechnology
  • CEO Mr. Stephen Allen Hurly M.B.A., M.Sc.
  • Employees 34
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.